Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.
New Haven, CT, United States.
UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.
Read more about the latest issues in cybersecurity
Digital forensics or digital forensic science is a branch of forensic science focused on the ...
Vendor risk management (VRM) deals with the management and monitoring of risks resulting from ...
Compare Biohaven Pharmaceuticals's security performance with other companies